Acute decompensated heart failure: Contemporary medical management

Susan M. Joseph, Ari M. Cedars, Gregory A. Ewald, Edward M. Geltman, Douglas L. Mann

Research output: Contribution to journalReview article

66 Citations (Scopus)

Abstract

Hospitalizations for acute decompensated heart failure are increasing in the United States. Moreover, the prevalence of heart failure is increasing consequent to an increased number of older individuals, as well as to improvement in therapies for coronary artery disease and sudden cardiac death that have enabled patients to live longer with cardiovascular disease. The main treatment goals in the hospitalized patient with heart failure are to restore euvolemia and to minimize adverse events. Common in-hospital treatments include intravenous diuretics, vasodilators, and inotropic agents. Novel pharmaceutical agents have shown promise in the treatment of acute decompensated heart failure and may simplify the treatment and reduce the morbidity associated with the disease. This review summarizes the contemporary management of patients with acute decompensated heart failure.

Original languageEnglish (US)
Pages (from-to)510-520
Number of pages11
JournalTexas Heart Institute Journal
Volume36
Issue number6
StatePublished - Dec 1 2009
Externally publishedYes

Fingerprint

Heart Failure
Therapeutics
Sudden Cardiac Death
Vasodilator Agents
Diuretics
Coronary Artery Disease
Hospitalization
Cardiovascular Diseases
Morbidity
Pharmaceutical Preparations

Keywords

  • Acute disease
  • Aged
  • Cardiac output, low
  • Disease progression
  • Diuretics
  • Furosemide
  • Heart failure/classification/drug therapy/mortality
  • Hospitalization
  • Length of stay
  • Milrinone
  • Morbidity/trends
  • Relaxin
  • Tolvaptan
  • Ultrafiltration
  • United states/epidemiology
  • Vasodilator agents
  • Ventricular dysfunction, left

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Joseph, S. M., Cedars, A. M., Ewald, G. A., Geltman, E. M., & Mann, D. L. (2009). Acute decompensated heart failure: Contemporary medical management. Texas Heart Institute Journal, 36(6), 510-520.

Acute decompensated heart failure : Contemporary medical management. / Joseph, Susan M.; Cedars, Ari M.; Ewald, Gregory A.; Geltman, Edward M.; Mann, Douglas L.

In: Texas Heart Institute Journal, Vol. 36, No. 6, 01.12.2009, p. 510-520.

Research output: Contribution to journalReview article

Joseph, SM, Cedars, AM, Ewald, GA, Geltman, EM & Mann, DL 2009, 'Acute decompensated heart failure: Contemporary medical management', Texas Heart Institute Journal, vol. 36, no. 6, pp. 510-520.
Joseph SM, Cedars AM, Ewald GA, Geltman EM, Mann DL. Acute decompensated heart failure: Contemporary medical management. Texas Heart Institute Journal. 2009 Dec 1;36(6):510-520.
Joseph, Susan M. ; Cedars, Ari M. ; Ewald, Gregory A. ; Geltman, Edward M. ; Mann, Douglas L. / Acute decompensated heart failure : Contemporary medical management. In: Texas Heart Institute Journal. 2009 ; Vol. 36, No. 6. pp. 510-520.
@article{5d65212e692d41eeb827a9108bd189ab,
title = "Acute decompensated heart failure: Contemporary medical management",
abstract = "Hospitalizations for acute decompensated heart failure are increasing in the United States. Moreover, the prevalence of heart failure is increasing consequent to an increased number of older individuals, as well as to improvement in therapies for coronary artery disease and sudden cardiac death that have enabled patients to live longer with cardiovascular disease. The main treatment goals in the hospitalized patient with heart failure are to restore euvolemia and to minimize adverse events. Common in-hospital treatments include intravenous diuretics, vasodilators, and inotropic agents. Novel pharmaceutical agents have shown promise in the treatment of acute decompensated heart failure and may simplify the treatment and reduce the morbidity associated with the disease. This review summarizes the contemporary management of patients with acute decompensated heart failure.",
keywords = "Acute disease, Aged, Cardiac output, low, Disease progression, Diuretics, Furosemide, Heart failure/classification/drug therapy/mortality, Hospitalization, Length of stay, Milrinone, Morbidity/trends, Relaxin, Tolvaptan, Ultrafiltration, United states/epidemiology, Vasodilator agents, Ventricular dysfunction, left",
author = "Joseph, {Susan M.} and Cedars, {Ari M.} and Ewald, {Gregory A.} and Geltman, {Edward M.} and Mann, {Douglas L.}",
year = "2009",
month = "12",
day = "1",
language = "English (US)",
volume = "36",
pages = "510--520",
journal = "Texas Heart Institute Journal",
issn = "0730-2347",
publisher = "Texas Heart Institute",
number = "6",

}

TY - JOUR

T1 - Acute decompensated heart failure

T2 - Contemporary medical management

AU - Joseph, Susan M.

AU - Cedars, Ari M.

AU - Ewald, Gregory A.

AU - Geltman, Edward M.

AU - Mann, Douglas L.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Hospitalizations for acute decompensated heart failure are increasing in the United States. Moreover, the prevalence of heart failure is increasing consequent to an increased number of older individuals, as well as to improvement in therapies for coronary artery disease and sudden cardiac death that have enabled patients to live longer with cardiovascular disease. The main treatment goals in the hospitalized patient with heart failure are to restore euvolemia and to minimize adverse events. Common in-hospital treatments include intravenous diuretics, vasodilators, and inotropic agents. Novel pharmaceutical agents have shown promise in the treatment of acute decompensated heart failure and may simplify the treatment and reduce the morbidity associated with the disease. This review summarizes the contemporary management of patients with acute decompensated heart failure.

AB - Hospitalizations for acute decompensated heart failure are increasing in the United States. Moreover, the prevalence of heart failure is increasing consequent to an increased number of older individuals, as well as to improvement in therapies for coronary artery disease and sudden cardiac death that have enabled patients to live longer with cardiovascular disease. The main treatment goals in the hospitalized patient with heart failure are to restore euvolemia and to minimize adverse events. Common in-hospital treatments include intravenous diuretics, vasodilators, and inotropic agents. Novel pharmaceutical agents have shown promise in the treatment of acute decompensated heart failure and may simplify the treatment and reduce the morbidity associated with the disease. This review summarizes the contemporary management of patients with acute decompensated heart failure.

KW - Acute disease

KW - Aged

KW - Cardiac output, low

KW - Disease progression

KW - Diuretics

KW - Furosemide

KW - Heart failure/classification/drug therapy/mortality

KW - Hospitalization

KW - Length of stay

KW - Milrinone

KW - Morbidity/trends

KW - Relaxin

KW - Tolvaptan

KW - Ultrafiltration

KW - United states/epidemiology

KW - Vasodilator agents

KW - Ventricular dysfunction, left

UR - http://www.scopus.com/inward/record.url?scp=76149106490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76149106490&partnerID=8YFLogxK

M3 - Review article

C2 - 20069075

AN - SCOPUS:76149106490

VL - 36

SP - 510

EP - 520

JO - Texas Heart Institute Journal

JF - Texas Heart Institute Journal

SN - 0730-2347

IS - 6

ER -